Reader-Supported · Editorially Reviewed
§ Medication Guide

How to Get Zepbound Online (Tirzepatide) in 2026

Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.

Last reviewed June 2026
4 studies cited
0 Verified OffersIndependent Review

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

No verified affiliate offer for this medication

This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.

Zepbound is Eli Lilly's tirzepatide injection, FDA-approved in November 2023 for chronic weight management and the only dual GIP + GLP-1 receptor agonist with an obesity indication. The SURMOUNT-1 trial (NEJM 2022) reported 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks by the treatment-regimen estimand, versus 3.1% with placebo. A trial average is not an individual prediction. Prices and coverage depend on dose, presentation, pharmacy, and insurance; confirm current terms directly. This guide explains the medication and access considerations without inferring a provider-specific offer.

What It Is

Zepbound contains tirzepatide, a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors, mechanistically distinct from semaglutide which targets GLP-1 alone. FDA-approved November 2023 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. In 2024 the label was expanded to cover obstructive sleep apnea in adults with obesity (SURMOUNT-OSA trial). Available as auto-injector pens (5 dose strengths: 2.5, 5, 7.5, 10, 12.5, 15 mg) and as single-dose vials through LillyDirect at lower cash-pay rates.

Who It's For

Adults with BMI ≥30, or BMI ≥27 with hypertension, type 2 diabetes, dyslipidaemia, or OSA. Particularly strong fit for patients who have plateaued on semaglutide and want the additional weight-loss potential of dual-receptor agonism, or for patients with comorbid OSA who can leverage the dual indication. Same MTC/MEN-2 contraindications as Wegovy. Patients with severe gastroparesis or active pancreatitis should be evaluated carefully.

What To Expect

Standard 16-week titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, escalating every 4 weeks if tolerated. Most patients can stop at the 10 mg or 12.5 mg dose if they hit goal weight. LillyDirect cash-pay vials are $349/mo (5 mg) and $549/mo (7.5 mg+) for self-pay patients, currently the cheapest legitimate route. Pen format runs $1,000–$1,300/mo at retail without insurance, dropping to $400–$700/mo with the Lilly savings card on commercial plans. Through telehealth all-in expect $400–$900/mo depending on whether the platform sources from LillyDirect vials or retail pens. Side-effect profile similar to Wegovy: nausea (29%), diarrhoea (23%), constipation (17%) per SURMOUNT-1.

Verified Offers for Zepbound

0 verified
We do not currently have a verified affiliate destination specifically mapped to this medication. We do not substitute a general category or different-medication offer on this guide.

Zepbound vs. Wegovy: How Tirzepatide's Dual Mechanism Changes the Math

Zepbound (tirzepatide) activates two receptors. GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), while Wegovy (semaglutide) targets GLP-1 alone. The dual mechanism appears to produce greater weight loss in head-to-head data: the SURMOUNT-5 trial (2024) found tirzepatide 10–15 mg produced 20.2% mean body weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks, a meaningful difference in absolute terms, roughly 15 lbs more lost on tirzepatide for a 200 lb patient. See also the SURMOUNT-1 primary publication (NEJM 2022) for the full efficacy and safety data.

The GIP receptor activation is thought to improve the tolerability profile: SURMOUNT-1 (NEJM 2022) reported lower rates of nausea (29%) and vomiting (12%) compared to Wegovy's STEP 1 data (NEJM 2021) (44% nausea, 25% vomiting). This makes Zepbound a particularly strong option for patients who tried semaglutide and discontinued due to GI side effects.

Cost is the main counterargument. LillyDirect vials are $349–$549/month, and most telehealth platforms price all-in at $400–$900/month, higher than the NovoCare Wegovy cash-pay floor of $499/month for all dose tiers. The decision rule: if you have no insurance coverage and cost is the primary constraint, Wegovy via NovoCare is cheaper. If you have commercial insurance that covers both, or if you previously discontinued semaglutide due to GI side effects, Zepbound is the stronger clinical choice.

LillyDirect Cash-Pay: What It Is and How to Access It Through Telehealth

LillyDirect is Eli Lilly's direct-to-patient pharmacy program, launched in 2024 to offer Zepbound single-dose vials at a lower cash-pay price than retail pens. The vials are priced at $349/month for the 2.5 and 5 mg doses, and $549/month for 7.5 mg and above. To access LillyDirect pricing, you need a valid Zepbound prescription from a licensed US clinician, which is where telehealth platforms come in.

Most telehealth platforms that offer Zepbound can route your prescription to LillyDirect. The practical workflow: complete your telehealth intake and receive a prescription, then either the platform routes it to LillyDirect directly, or you take the prescription to LillyDirect.com yourself. FuturHealth, TMates, and TrimRx all have documented LillyDirect routing workflows. Note that vials require self-injection with a separate syringe. If you prefer the auto-injector pen format, you'll pay retail pricing (~$1,000–$1,300/month without insurance).

The LillyDirect savings card is separate from the vial program: it's for the pen format on commercial insurance and can reduce copays to as low as $25/month for covered patients. The savings card cannot be used with Medicare, Medicaid, or other government programs. If you have commercial insurance, the savings card route is almost always cheaper than cash-pay vials.

§ Clinical Evidence

What the Studies Actually Show

Zepbound is FDA-approved tirzepatide for chronic weight management. The evidence below comes from the SURMOUNT trials (which led to the 2023 obesity approval) and the SURMOUNT-OSA trial (which led to the 2024 OSA-in-obesity approval).

EndpointFinding
Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1−20.9% body weight vs −3.1% placebo in adults with obesity without diabetes
Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2−14.7% body weight in adults with type 2 diabetes
Sleep apnea (SURMOUNT-OSA)3Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity
GI side effects (FDA prescribing information)4Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5%
Boxed warning4Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2
A1C reduction (T2D, SURPASS program)5≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5
Compounded tirzepatide — evidence basis6Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products
§ FAQ

Frequently Asked Questions

How much does Zepbound cost without insurance in 2026?

LillyDirect cash-pay vials are the cheapest route at $349/mo for the 5 mg dose and $549/mo for 7.5 mg+ doses. Pen format at retail runs $1,000–$1,300/mo without the Lilly savings card. Through telehealth platforms expect $400–$900/mo all-in. Vials require self-administration with a syringe (telehealth platforms provide instruction); pens are pre-loaded auto-injectors but cost more.

What is the difference between Zepbound and Mounjaro?

Both contain tirzepatide and dose identically. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management and OSA. The drugs are biochemically interchangeable but insurance and pharmacy systems treat them as separate SKUs because of the indication, and pharmacies cannot freely substitute one for the other.

Is Zepbound more effective than Wegovy?

In an indirect comparison: the SURMOUNT-1 trial (NEJM 2022) reported 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks; STEP 1 reported 14.9% with semaglutide 2.4 mg at 68 weeks. Those separate trials are not a head-to-head comparison. SURMOUNT-5 (2025) directly compared the medications and reported 20.2% mean weight loss with tirzepatide versus 13.7% with semaglutide at 72 weeks in the studied population. Individual response and tolerability vary; a prescriber should assess the appropriate treatment.

Which telehealth providers prescribe Zepbound?

Within our reviewed network: TMates, TrimRx, MEDVi, Eden, GetThinMD, SkinnyRx, FuturHealth, JRNYS, PlushCare, and Ro all dispense FDA-approved brand-name Zepbound. Several (Eden, MEDVi, FuturHealth) source from LillyDirect vials when available, which keeps the cash-pay price closer to $400–$600/mo all-in. Ask explicitly whether the platform is dispensing pens or vials before signing up.

Does insurance cover Zepbound?

Commercial insurance coverage improved with the 2024 OSA label expansion; plans that exclude obesity GLP-1s often cover Zepbound when prescribed for OSA in patients with obesity. The Lilly savings card can drop commercial copays to ~$25/mo for covered patients. Medicare Part D does not cover Zepbound for weight loss but does cover it for OSA. Medicaid varies by state.

Vials vs pens, which should I choose?

Vials (LillyDirect): cheaper ($349–$549/mo), require drawing the dose with a syringe, more flexibility in dose adjustments. Pens: pre-loaded, easier self-administration, more expensive. For most needle-comfortable patients, vials offer better economics. Vial dispensing is currently dose-locked to 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg; LillyDirect ships a 4-week supply at the prescribed dose.

How long do I need to stay on Zepbound?

Like Wegovy, Zepbound is intended for long-term therapy. The SURMOUNT-4 extension trial (NEJM 2024) showed patients who continued tirzepatide at week 36 maintained or improved their weight loss; those who switched to placebo regained 14% of lost weight within a year. Plan for indefinite therapy unless you achieve goal weight and your clinician supports a structured taper plus lifestyle maintenance.

What side effects should I expect?

GI events dominate the titration phase per the SURMOUNT-1 trial (NEJM 2022): nausea in 29% of patients, diarrhoea in 23%, constipation in 17%, vomiting in 12%. Most resolve as the dose stabilises. Serious risks: pancreatitis, gallbladder disease, severe GI events requiring hospitalisation in <1%. The boxed warning covers MTC risk per rodent studies. Hypoglycaemia is rare in non-diabetic patients but possible in patients on insulin or sulfonylureas.

References — Clinical Studies
  1. SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
  2. SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
  3. SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
  4. SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.

RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.